Preferences of physicians and patients for cell therapies in advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, cross-sectional study using a discrete choice experiment to measure how oncology physicians and patients weigh different treatment attributes. Participants will be exposed to hypothetical cell therapy profiles and choose between them, allowing researchers to quantify preferences for efficacy, safety, treatment burden, and cost. The study will use a structured, ISPOR-guided approach to develop attributes and analyze data with mixed logit models, latent class analysis, and sensitivity checks. It involves about 420 physicians and 600 patients in China and compares physician versus patient preferences. Results will highlight which attributes drive decision-making and potential differences between groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Physicians

Physicians must meet ALL of the following criteria:

1. Hold a valid medical practitioner license issued in the People's Republic of China and currently practice at a medical institution in China;
2. Specialize in medical oncology or another specialty directly involved in the diagnosis and treatment of solid tumors (e.g., thoracic oncology, gastrointestinal oncology, genitourinary oncology, or gynecologic oncology; surgical oncologists or radiation oncologists with prescribing authority for systemic anticancer therapy are also eligible);
3. Hold a professional title of attending physician or above;
4. Have directly participated in systemic treatment decision-making for patients with advanced (unresectable stage III or stage IV) solid tumors within the past 12 months;
5. Have a basic understanding of cell therapies (e.g., CAR-T, TIL, TCR-T, and NK cell therapies) and their therapeutic principles;
6. Participate voluntarily and provide electronic informed consent.

   * Patients

Patients must meet ALL of the following criteria:

1. Aged 18 years or older;
2. Histologically or cytologically confirmed advanced solid tumor (unresectable stage III or stage IV; e.g., non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, gastric cancer, melanoma, or ovarian cancer);
3. Received at least one prior line of systemic anticancer therapy (chemotherapy, targeted therapy, immune checkpoint inhibitors, or other cellular immunotherapy) in the advanced or metastatic setting;
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with adequate cognitive and physical capacity to complete the questionnaire;
5. Able to understand the questionnaire content independently or with assistance from a study coordinator;
6. Participate voluntarily and provide electronic informed consent.

Exclusion Criteria:

* Physicians

Physicians meeting ANY of the following criteria will be excluded:

1. Individuals engaged exclusively in basic research without direct involvement in clinical patient care;
2. Individuals unable, for any reason, to understand the questionnaire content or make independent judgments.

   * Patients

Patients meeting ANY of the following criteria will be excluded:

1. Patients who are unaware of their tumor stage or treatment status;
2. Severe cognitive impairment or psychiatric disorders that preclude comprehension of the questionnaire content or independent judgment;
3. Estimated life expectancy of less than 3 months as assessed by the treating physician, or insufficient physical capacity to complete the questionnaire;
4. Uncontrolled acute illness or other urgent medical conditions that make study participation inadvisable.

Where it's running

• The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Weijia Fang, M.D.
• Email: weijiafang@zju.edu.cn
• Phone: 86-057187237587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BA1203 in advanced solid tumors: safety and early signs of activity

  This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.

  Recruiting Phase 1 Shandong Boan Biotechnology Co., Ltd · Beijing · NCT07876609

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• REC-7735 for PIK3CA-H1047R-mutant solid tumors

  This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.

  Recruiting at 3 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Grand Rapids, Michigan and 2 other locations · NCT07819136

• HP007 monotherapy for relapsed or advanced solid tumors

  This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting Phase 1 Parr Biotechnology (Hebei) Co., Ltd. · Changchun, Jilin · NCT07800936

• ONO-7429 in advanced or recurrent solid tumors

  This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.

  Recruiting at 10 sites Phase 1 Ono Pharmaceutical Co., Ltd. · Kashiwa, Chiba and 9 other locations · NCT07787208

• BL-M08D in patients with digestive tract and other solid tumors

  A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07780318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.